Intertrust Group: Elian Acquisition Update - All Regulatory Approvals Obtained, Transaction Closing

Intertrust Group: Elian Acquisition Update - All Regulatory Approvals Obtained, Transaction Closing by End of September

ID: 494286

(Thomson Reuters ONE) -


Elian Acquisition Update
All Regulatory Approvals Obtained, Transaction Closing by End of September

Amsterdam - September 13, 2016 - Intertrust N.V. ("Intertrust" or "the Company")
[ticker symbol INTER] a leading global provider of high-value trust and
corporate services, announces that all regulatory approvals required for
completion of the Elian acquisition have now been received. The transaction is
expected to close as previously announced in September 2016.   Subsequently, the
integration process will commence as planned, including management structure,
financial consolidation, system integration, joint commercial market approach,
co-location of employees in the 10 jurisdictions in which Intertrust and Elian
both have a presence, and rebranding of Elian to Intertrust.



For further information
Intertrust N.V. annelouise.metz(at)intertrustgroup.com

Anne Louise Metz Tel: +31 20 577 1157

Director of Investors Relations, Marketing
& Communications


About Intertrust
Intertrust is a leading global provider of high-value trust and corporate
services, with a network of 37 offices in 26 jurisdictions across Europe, the
Americas, Asia and the Middle-East. The Company focuses on delivering high-
quality tailored services to its clients with a view to building long-term
relationships. Intertrust's business services offering is comprised of corporate
services, fund services, capital market services, and private client services.
Intertrust has leading market positions in selected key geographic markets of
its industry, including the Netherlands, Luxembourg, the Cayman Islands and
Guernsey.  After closing the Elian acquisition, Intertrust will have offices in
30 jurisdictions including the important jurisdiction of Jersey.




Intertrust NV Press release:
http://hugin.info/171118/R/2041651/761886.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Intertrust Group via GlobeNewswire




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Leading medical journal publishes treatment effect of Santhera's Raxone on inspiratory function in patients with Duchenne muscular dystrophy (DMD) Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America
Bereitgestellt von Benutzer: hugin
Datum: 13.09.2016 - 07:15 Uhr
Sprache: Deutsch
News-ID 494286
Anzahl Zeichen: 2521

contact information:
Town:

Amsterdam



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 206 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Intertrust Group: Elian Acquisition Update - All Regulatory Approvals Obtained, Transaction Closing by End of September"
steht unter der journalistisch-redaktionellen Verantwortung von

Intertrust Group (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Intertrust Group



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z